2 475

Cited 0 times in

Use of contraceptive methods and contraceptive recommendations among health care providers actively involved in contraceptive counseling -- results of an international survey in 10 countries.

Authors
 June Koo Lee  ;  Heae Surng Park  ;  Dong-Wan Kim  ;  Kimary Kulig  ;  Tae Min Kim  ;  Se-Hoon Lee  ;  Yoon-Kyung Jeon  ;  Doo Hyun Chung  ;  Dae Seog Heo  ;  Woo-Ho Kim  ;  Yung-Jue Bang 
Citation
 CONTRACEPTION, Vol.86(6) : 631-638, 2012 
Journal Title
CONTRACEPTION
ISSN
 0010-7824 
Issue Date
2012
MeSH
Adult ; Contraception/adverse effects ; Contraception/methods* ; Contraception Behavior* ; Contraceptive Agents, Female/administration & dosage ; Contraceptive Agents, Female/adverse effects ; Family ; Female ; General Practitioners ; Global Health* ; Gynecology/manpower ; Humans ; Intrauterine Devices, Medicated/adverse effects ; Levonorgestrel/administration & dosage ; Levonorgestrel/adverse effects ; Male ; Middle Aged ; Midwifery* ; Obstetrics/manpower ; Patient Education as Topic ; Practice Patterns, Physicians'* ; Pregnancy ; Professional Practice*
Keywords
Contraception ; Counseling ; Health care providers
Abstract
BACKGROUND:
The purpose of this study was to investigate the overall survival (OS) of patients with advanced ALK-positive nonsmall cell lung cancer (NSCLC) who were managed in the pre-ALK inhibitor era and to compare their survival with that of a matched case cohort of ALK wild-type (WT) patients.
METHODS:
Data from 1166 patients who had stage IIIB/IV NSCLC with nonsquamous histology were collected from the NSCLC database of Seoul National University Hospital between 2003 and 2009. ALK fluorescence in situ hybridization (FISH) was used to analyze 262 patients who either had the WT epidermal growth factor receptor (EGFR) or were nonresponders to previous EGFR tyrosine kinase inhibitor (TKI) therapy. Overall survival (OS) was compared between 3 groups: 1) ALK-positive patients, 2) EGFR mutation-positive patients, and 3) ALK-WT/EGFR-WT patients. Progression-free survival (PFS) after first-line chemotherapy and EGFR TKIs also was analyzed.
RESULTS:
Twenty-three patients were ALK-positive according to FISH analysis and did not receive ALK inhibitors during follow-up. The median OS for ALK-positive patients, EGFR mutation-positive patients, and WT/WT patients was 12.2 months, 29.6 months, and 19.3 months, respectively (vs EGFR mutation-positive patients, P = .001; vs WT/WT, P = .127). The PFS after first-line chemotherapy for the 3 groups was not different. However, the PFS for patients who received EGFR TKIs was shorter in ALK-positive patients compared with the other 2 groups (vs EGFR mutation-positive patients, P < .001; vs WT/WT, P < .021).
CONCLUSIONS:
In the pre-ALK inhibitor era, ALK-positive patients experienced the shortest survival, although it did not differ statistically from that of WT/WT patients. Although their responses to platinum-based chemotherapy were not different from comparator groups, ALK-positive patients were even more resistant to EGFR TKI treatment than WT/WT patients.
Full Text
http://www.sciencedirect.com/science/article/pii/S0010782412004167
DOI
22770797
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Si Hyun(조시현) ORCID logo https://orcid.org/0000-0003-2718-6645
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/90069
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links